Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicentre Observational Study

Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY

The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with irreversible loss of vision on an individual-based level over 2 years. The main objectives of this study are: * Identify and quantify focal and global alterations in the retina in regard to disease progression. * Assess the individual risk of disease progression in intermediate AMD patients converting to advanced AMD based on imaging. * Specify the course of disease in regard to the sequence of events that lead to the conversion to advanced AMD * Enhance the ability to classify AMD using artificial intelligence in addition to traditional models. All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures: * Scanning Laser Fundus Photography * Color Fundus Photography (CFP) * Optical Coherence Tomography (OCT) * Optical Coherence Tomography Angiography (OCTA) Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out. No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 99
Healthy Volunteers: f
View:

• Age: 55-99 years old

• Early or intermediate AMD in at least one eye (drusen \> 63 µm and/or any definite hyper- or hypopigmentary abnormalities with or without reticular pseudodrusen)

• If both eyes are eligible, both eyes will be included in the cohort study.

• Clear optical media and adequate pupillary dilation for imaging and functional testing.

Locations
Other Locations
Austria
Medical University of Vienna
NOT_YET_RECRUITING
Vienna
France
CHU Dijon
RECRUITING
Dijon
Slovenia
University Medical Center Ljubljana
RECRUITING
Ljubljana
Spain
Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomed
RECRUITING
Barcelona
Switzerland
Vista Klinik Binningen
RECRUITING
Binningen
University of Zürich
RECRUITING
Zurich
United Kingdom
Queen's Unviversity Belfast
RECRUITING
Belfast
Contact Information
Primary
Gregor Reiter, Priv.-Doz. Ing. DDr., BA MSc
gregor.reiter@meduniwien.ac.at
+43 1 40400-73419
Time Frame
Start Date: 2025-02-25
Estimated Completion Date: 2027-07
Participants
Target number of participants: 500
Related Therapeutic Areas
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Collaborators: University Medical Centre Ljubljana, Fundacion Clinic per a la Recerca Biomédica, Centre Hospitalier Universitaire Dijon, Vista Klinik, Queen's University, Belfast, University of Zurich
Leads: Medical University of Vienna

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicenter Observational Study

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicenter Observational Study

Enrollment Status: Recruiting
Publish Date: May 15, 2025

Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Enrollment Status: Recruiting
Publish Date: November 26, 2024
Intervention Type: Drug

Village-Integrated Eye Worker Trial II (VIEW II):A Cluster-randomized Trial of the Effectiveness of Community-based Ocular Disease Screening

Village-Integrated Eye Worker Trial II (VIEW II):A Cluster-randomized Trial of the Effectiveness of Community-based Ocular Disease Screening

Who is this study for: Patients with Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Enrollment Status: Recruiting
Publish Date: July 11, 2025
Intervention Type: Other
Study Phase: Not Applicable
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved